{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Pathologies&page=31",
    "query": {
      "condition": "Multiple Pathologies",
      "page": 31
    },
    "page_size": 10
  },
  "pagination": {
    "page": 31,
    "page_size": 10,
    "total_count": 3386,
    "total_pages": 339,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Pathologies&page=32&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Multiple+Pathologies&page=30&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-07T08:44:26.956Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT02343003",
      "title": "Nerve Ablation by Cooled Radiofrequency Compared to Corticosteroid Injection for Management of Knee Pain",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Osteoarthritis of the Knee"
      ],
      "interventions": [
        {
          "name": "Cooled Radiofrequency",
          "type": "DEVICE"
        },
        {
          "name": "Corticosteroid injection",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DEVICE",
        "DRUG"
      ],
      "sponsor": "Halyard Health",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "21 Years and older"
      },
      "enrollment_count": 151,
      "start_date": "2015-01",
      "completion_date": "2017-03-16",
      "has_results": true,
      "last_update_posted_date": "2019-05-13",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 11,
      "location_summary": "Phoenix, Arizona • Scottsdale, Arizona • Santa Monica, California + 8 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Maple Grove",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02343003"
    },
    {
      "nct_id": "NCT05552469",
      "title": "Dose Optimization and Expansion Study of DFV890 in Adult Patients With Myeloid Diseases",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Myeloid Diseases"
      ],
      "interventions": [
        {
          "name": "DFV890",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "100 Years",
        "sex": "ALL",
        "summary": "18 Years to 100 Years"
      },
      "enrollment_count": 71,
      "start_date": "2023-05-08",
      "completion_date": "2027-02-01",
      "has_results": false,
      "last_update_posted_date": "2026-09-10",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 11,
      "location_summary": "Stanford, California • Tampa, Florida • Chicago, Illinois + 7 more",
      "locations": [
        {
          "city": "Stanford",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Baltimore",
          "state": "Maryland"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05552469"
    },
    {
      "nct_id": "NCT01148810",
      "title": "Efficacy and Tolerability of BAF312 in Patients With Polymyositis and Dermatomyositis",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Polymyositis",
        "Dermatomyositis"
      ],
      "interventions": [
        {
          "name": "BAF312",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 18,
      "start_date": "2010-06-15",
      "completion_date": "2012-06-13",
      "has_results": true,
      "last_update_posted_date": "2019-04-25",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01148810"
    },
    {
      "nct_id": "NCT05122559",
      "title": "Neuroprotection With N-acetyl Cysteine for Patients With Progressive Multiple Sclerosis",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Multiple Sclerosis",
        "Multiple Sclerosis, Primary Progressive",
        "Multiple Sclerosis, Secondary Progressive"
      ],
      "interventions": [
        {
          "name": "N-acetyl cysteine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Emmanuelle Waubant, MD PhD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "70 Years",
        "sex": "ALL",
        "summary": "40 Years to 70 Years"
      },
      "enrollment_count": 98,
      "start_date": "2022-02-16",
      "completion_date": "2027-02",
      "has_results": false,
      "last_update_posted_date": "2026-03-11",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 1,
      "location_summary": "San Francisco, California",
      "locations": [
        {
          "city": "San Francisco",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05122559"
    },
    {
      "nct_id": "NCT03299686",
      "title": "Study to Assess the Efficacy and Safety of CJM112 in Patients With Inadequately Controlled Severe Asthma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Asthma"
      ],
      "interventions": [
        {
          "name": "CJM112",
          "type": "DRUG"
        },
        {
          "name": "Placebo to CJM112",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "18 Years to 75 Years"
      },
      "enrollment_count": 118,
      "start_date": "2017-11-06",
      "completion_date": "2019-07-08",
      "has_results": true,
      "last_update_posted_date": "2021-10-08",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 8,
      "location_summary": "Fullerton, California • Riverside, California • Denver, Colorado + 5 more",
      "locations": [
        {
          "city": "Fullerton",
          "state": "California"
        },
        {
          "city": "Riverside",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03299686"
    },
    {
      "nct_id": "NCT04205409",
      "title": "Nivolumab for Relapsed, Refractory, or Detectable Disease Post Chimeric Antigen Receptor T-cell Treatment in Patients With Hematologic Malignancies",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Recurrent Chronic Lymphocytic Leukemia",
        "Recurrent Diffuse Large B-Cell Lymphoma",
        "Recurrent Follicular Lymphoma",
        "Recurrent Grade 1 Follicular Lymphoma",
        "Recurrent Grade 2 Follicular Lymphoma",
        "Recurrent Grade 3 Follicular Lymphoma",
        "Recurrent Grade 3a Follicular Lymphoma",
        "Recurrent Marginal Zone Lymphoma",
        "Recurrent Non-Hodgkin Lymphoma",
        "Recurrent Plasma Cell Myeloma",
        "Refractory Chronic Lymphocytic Leukemia",
        "Refractory Diffuse Large B-Cell Lymphoma",
        "Refractory Follicular Lymphoma",
        "Refractory Marginal Zone Lymphoma",
        "Refractory Non-Hodgkin Lymphoma",
        "Refractory Plasma Cell Myeloma",
        "Recurrent Mantle Cell Lymphoma",
        "Refractory Mantle Cell Lymphoma"
      ],
      "interventions": [
        {
          "name": "Nivolumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "University of Washington",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 20,
      "start_date": "2020-06-05",
      "completion_date": "2026-01-05",
      "has_results": true,
      "last_update_posted_date": "2026-06-26",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 1,
      "location_summary": "Seattle, Washington",
      "locations": [
        {
          "city": "Seattle",
          "state": "Washington"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04205409"
    },
    {
      "nct_id": "NCT02675452",
      "title": "AMG 176 First in Human Trial in Participants With Relapsed or Refractory Multiple Myeloma and Participants With Relapsed or Refractory Acute Myeloid Leukemia",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Relapsed or Refractory Multiple Myeloma",
        "Relapsed or Refractory Acute Myeloid Leukemia"
      ],
      "interventions": [
        {
          "name": "AMG 176",
          "type": "DRUG"
        },
        {
          "name": "Azacitidine",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "85 Years",
        "sex": "ALL",
        "summary": "18 Years to 85 Years"
      },
      "enrollment_count": 141,
      "start_date": "2016-06-13",
      "completion_date": "2024-05-27",
      "has_results": true,
      "last_update_posted_date": "2025-07-09",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 10,
      "location_summary": "Duarte, California • Sacramento, California • Aurora, Colorado + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02675452"
    },
    {
      "nct_id": "NCT03398538",
      "title": "Resorbable Glass Fiber Matrix in the Treatment of Diabetic Foot Ulcers",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Diabetic Foot Ulcer",
        "Ulcer Foot",
        "Diabetic Foot"
      ],
      "interventions": [
        {
          "name": "Offloading",
          "type": "OTHER"
        },
        {
          "name": "Additional (outer) Dressing Application",
          "type": "OTHER"
        },
        {
          "name": "Mirragen Wound Matrix Dressing",
          "type": "OTHER"
        },
        {
          "name": "Fibracol Wound Dressing",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "OTHER"
      ],
      "sponsor": "ETS Wound Care, LLC",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 40,
      "start_date": "2017-12-26",
      "completion_date": "2018-10-31",
      "has_results": false,
      "last_update_posted_date": "2022-08-03",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 5,
      "location_summary": "St Louis, Missouri • Youngstown, Ohio • Martinsville, Virginia + 2 more",
      "locations": [
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Youngstown",
          "state": "Ohio"
        },
        {
          "city": "Martinsville",
          "state": "Virginia"
        },
        {
          "city": "Roanoke",
          "state": "Virginia"
        },
        {
          "city": "Troutville",
          "state": "Virginia"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03398538"
    },
    {
      "nct_id": "NCT04377555",
      "title": "Prospective Study to Assess Disease Activity and Biomarkers in Minority Participants With Relapsing Multiple Sclerosis (RMS) After Initiation and During Treatment With Ocrelizumab",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Multiple Sclerosis, Relapsing"
      ],
      "interventions": [
        {
          "name": "Ocrelizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Genentech, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 179,
      "start_date": "2020-07-30",
      "completion_date": "2025-11-11",
      "has_results": false,
      "last_update_posted_date": "2026-02-04",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 26,
      "location_summary": "Phoenix, Arizona • Los Angeles, California • Washington D.C., District of Columbia + 19 more",
      "locations": [
        {
          "city": "Phoenix",
          "state": "Arizona"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Washington D.C.",
          "state": "District of Columbia"
        },
        {
          "city": "Jacksonville Beach",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04377555"
    },
    {
      "nct_id": "NCT04335643",
      "title": "Telehealth CBT for Adolescents and Young Adults With Childhood-onset Systemic Lupus Erythematosus",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Systemic Lupus Erythematosus"
      ],
      "interventions": [
        {
          "name": "TEACH",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Michigan State University",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "22 Years",
        "sex": "ALL",
        "summary": "12 Years to 22 Years"
      },
      "enrollment_count": 65,
      "start_date": "2020-08-04",
      "completion_date": "2024-10-16",
      "has_results": false,
      "last_update_posted_date": "2025-02-13",
      "last_synced_at": "2026-11-07T08:44:26.956Z",
      "location_count": 1,
      "location_summary": "Grand Rapids, Michigan",
      "locations": [
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04335643"
    }
  ]
}